跳至主要内容
临床试验/NCT05818618
NCT05818618已完成不适用

Impact of Topical Clobetasol on Gingival Crevicular Fluid miRNAs in Subjects Affected by Oral Lichen Planus: a Randomized Clinical Trial

University of Catania2 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2020年3月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
62
试验地点
2
主要终点
miRNAs GCF levels

研究概览

简要总结

According to recent research, microRNAs (miRNAs) may function as early disease indicators and contribute to the severity of a number of precancerous and malignant oral disorders. The aim of the present study, through a double-blind randomized controlled trial design, is to analyze in the gingival crevicular fluid (GCF) as a non-invasive approach the impact of topical clobetasol on miRNAs expression in subjects affected by oral lichen planus (OLP).

详细描述

A double-blind randomized controlled clinical trial is conducted in order to evaluate the impact of topical clobetasol on GCF miRNAs expression in subjects with OLP and determine the statistical significance of the outcome variables.

At least 60 patients with OLP, randomly allocated in two groups: placebo group with a 4% hydroxyethyl cellulose adhesive gel and the clobetasol group with the same gel containing clobetasol propionate 0,05%.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

Sealed envelopes

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The complete correspondence of the most recent WHO clinical and histopathological criteria (2020) for OLP diagnosis.

排除标准

  • 1) Previous therapies for OLP during the last six months preceding the study; 2) State of pregnancy or breastfeeding; 3) Contact or drug oral lichenoid lesions; 4) Allergies to the molecules used in the study; 5) HIV seropositivity.

研究组 & 干预措施

Placebo

Placebo Comparator

Patients were treated with a topic placebo gel control

干预措施: Placebo (Drug)

Clobetasol propionate 0,05% gel

Active Comparator

Patients were treated with a topic gel of clobetasol propionate 0,05%

干预措施: Clobetasol Topical Gel (Drug)

结局指标

主要结局

miRNAs GCF levels

时间窗: 8 weeks

The level of expression of different miRNAs in the GCF before and after treatment in the two groups. (Scale 0-4)

miRNAs GCF levels

时间窗: 6 months

The level of expression of different miRNAs in the GCF before and after treatment in the two groups. (Scale 0-4)

次要结局

  • OLP disease severity scores(8 weeks)
  • OLP disease severity scores(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gaetano Isola

Researcher

University of Catania

研究点 (2)

Loading locations...

相似试验